Publication in Nature by OMass Founder, Professor Dame Carol Robinson, Shows Power of Native Mass Spectrometry in Drug Discovery by Capturing GPCR Signalling in Native Membrane Environment PRESS RELEASE Publication in Nature by OMass Founder, Professor Dame Carol Robinson, Shows Power of Native Mass Spectrometry in Drug Discovery by Capturing GPCR Signalling in Native Membrane...

OMass Establishes Scientific Advisory Board of Leading Experts in the Use of Biophysical Approaches to Drug Discovery PRESS RELEASE OMass Establishes Scientific Advisory Board of Leading Experts in the Use of Biophysical Approaches to Drug Discovery Oxford, United Kingdom – 7 March 2022 – OMass Therapeutics...

OMass’s OdyssION™ Drug Discovery Platform Makes Progress in Drugging the Undruggable, including Gasdermin D PRESS RELEASE OMass’s OdyssION™ Drug Discovery Platform Makes Progress in Drugging the Undruggable, including Gasdermin D Oxford, United Kingdom – 28 February 2022 – OMass Therapeutics (‘OMass’ or...

OMass Therapeutics to Present at Upcoming Conferences PRESS RELEASE OMass Therapeutics to Present at Upcoming Conferences Oxford, United Kingdom – 21 February 2022 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying...

OMass Unveils Rich Drug Discovery Pipeline Targeting Intractable or Inadequately Drugged Membrane and Complex-bound Proteins PRESS RELEASE OMass Unveils Rich Drug Discovery Pipeline Targeting Intractable or Inadequately Drugged Membrane and Complex-bound Proteins Oxford, United Kingdom – 4 November 2021 – OMass...